![Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology | SpringerLink Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12026-012-8268-8/MediaObjects/12026_2012_8268_Fig1_HTML.gif)
Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology | SpringerLink
![Cells | Free Full-Text | Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens Cells | Free Full-Text | Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens](https://pub.mdpi-res.com/cells/cells-08-00507/article_deploy/html/images/cells-08-00507-ag.png?1571589884)
Cells | Free Full-Text | Heterologous Immunity between Adenoviruses and Hepatitis C Virus (HCV): Recombinant Adenovirus Vaccine Vectors Containing Antigens from Unrelated Pathogens Induce Cross-Reactive Immunity Against HCV Antigens
![HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria - ScienceDirect HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1931312814002571-fx1.jpg)
HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria - ScienceDirect
![Repurposing Old Antibodies for New Diseases by Exploiting Cross Reactivity and Multicolored Nanoparticles | bioRxiv Repurposing Old Antibodies for New Diseases by Exploiting Cross Reactivity and Multicolored Nanoparticles | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2020/03/18/2020.03.17.995738/F1.large.jpg)
Repurposing Old Antibodies for New Diseases by Exploiting Cross Reactivity and Multicolored Nanoparticles | bioRxiv
![Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age | PNAS Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age | PNAS](https://www.pnas.org/cms/10.1073/pnas.2220320120/asset/5e8d54d9-4fee-45ab-8a2f-85ee161ae8b9/assets/images/large/pnas.2220320120fig02.jpg)
Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age | PNAS
![Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19 - ScienceDirect Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211124721005180-fx1.jpg)
Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19 - ScienceDirect
![A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells | EMBO Molecular Medicine A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/bf57f49f-ebd3-4ce0-8bc0-bbf88947b5be/emmm202215821-abs-0001-m.jpg)
A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells | EMBO Molecular Medicine
![Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-27674-x/MediaObjects/41467_2021_27674_Fig1_HTML.png)
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications
![Antibodies | Free Full-Text | Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology Antibodies | Free Full-Text | Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology](https://pub.mdpi-res.com/antibodies/antibodies-11-00048/article_deploy/html/images/antibodies-11-00048-g004.png?1657779540)
Antibodies | Free Full-Text | Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology
![Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions - ScienceDirect Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2666379121001567-fx1.jpg)
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions - ScienceDirect
Mechanism of Antigen Presentation and Specificity of Antibody Cross- Reactivity Elicited by an Oligosaccharide-Conjugate Cancer Vaccine | Journal of the American Chemical Society
Minimizing antibody cross-reactivity in multiplex detection of biomarkers in paper-based point-of-care assays - Nanoscale (RSC Publishing)
![Frontiers | Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases Frontiers | Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases](https://www.frontiersin.org/files/Articles/617089/fimmu-11-617089-HTML/image_m/fimmu-11-617089-g007.jpg)
Frontiers | Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases
![Figure 2 - Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection - Volume 23, Number 5—May 2017 - Emerging Infectious Diseases journal - CDC Figure 2 - Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection - Volume 23, Number 5—May 2017 - Emerging Infectious Diseases journal - CDC](https://wwwnc.cdc.gov/eid/images/16-1630-F2.jpg)
Figure 2 - Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection - Volume 23, Number 5—May 2017 - Emerging Infectious Diseases journal - CDC
![Manipulating the Selection Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies: Cell Manipulating the Selection Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies: Cell](https://www.cell.com/cms/attachment/6a0af54d-bb65-4cec-aab5-94dd217872dd/fx1_lrg.jpg)